secukinumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4934	1229022-83-6

Description:

Molecule	Description
Synonyms: secukinumab cosentyx AIN-457 AIN457	Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

secukinumab
cosentyx
AIN-457
AIN457

Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
10	mg	P

ADMET properties:

None

Approvals:

Show entries

Search:

Date	Agency	Company
Dec. 26, 2014	PMDA	Novartis Pharma
Jan. 14, 2015	EMA	NOVARTIS EUROPHARM LIMITED
Jan. 21, 2015	FDA	NOVARTIS PHARMS CORP

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	1203.85	15.14	5382	150156	1039383	62294101
Psoriasis	1111.42	15.14	1212	154326	85745	63247739
Psoriatic arthropathy	858.72	15.14	1089	154449	90431	63243053
Inappropriate schedule of product administration	834.79	15.14	1146	154392	102819	63230665
Incorrect dose administered	785.32	15.14	847	154691	59121	63274363
Liver injury	723.61	15.14	815	154723	59705	63273779
Musculoskeletal stiffness	535.67	15.14	1308	154230	183310	63150174
Toxicity to various agents	532.70	15.14	16	155522	247234	63086250
Device malfunction	531.59	15.14	401	155137	17456	63316028
Skin plaque	505.94	15.14	292	155246	8028	63325456

Showing 1 to 10 of 573 entries

Previous1 2 3 4 5…58Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	1622.81	15.01	2846	57746	453905	34442434
Inappropriate schedule of product administration	1134.42	15.01	906	59686	61390	34834949
Psoriasis	1088.62	15.01	733	59859	38079	34858260
Incorrect dose administered	860.50	15.01	646	59946	39869	34856470
Arthralgia	753.94	15.01	1177	59415	168864	34727475
Device malfunction	739.23	15.01	361	60231	10060	34886279
Psoriatic arthropathy	680.08	15.01	425	60167	19373	34876966
Skin plaque	601.88	15.01	245	60347	4369	34891970
Therapeutic product effect incomplete	596.46	15.01	575	60017	49966	34846373
Pain	548.29	15.01	1138	59454	203537	34692802

Showing 1 to 10 of 430 entries

Previous1 2 3 4 5…43Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	1194.32	14.91	1372	151012	132256	79459748
Psoriasis	1037.29	14.91	1055	151329	88532	79503472
Musculoskeletal stiffness	897.04	14.91	1368	151016	173640	79418364
Psoriatic arthropathy	881.86	14.91	907	151477	77092	79514912
Drug ineffective	806.48	14.91	4123	148261	1076790	78515214
Therapy interrupted	763.77	14.91	565	151819	30776	79561228
Acute kidney injury	739.71	14.91	70	152314	519334	79072670
Toxicity to various agents	732.83	14.91	15	152369	421525	79170479
Arthralgia	651.75	14.91	2480	149904	569323	79022681
Drug interaction	540.81	14.91	76	152308	415107	79176897

Showing 1 to 10 of 649 entries

Previous1 2 3 4 5…65Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L04AC10	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA EPC	N0000191495	Interleukin-17A Antagonist
FDA MoA	N0000191494	Interleukin-17A Antagonists

Showing 1 to 3 of 3 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Ankylosing spondylitis	indication	9631008	DOID:7147
Psoriatic arthritis	indication	156370009	DOID:9008
Plaque psoriasis	indication	200965009
Pustular psoriasis	indication	200973000
Non-radiographic axial spondyloarthritis	indication	713777005

Showing 1 to 5 of 5 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-17A	Cytokine	Q16552	IL17_HUMAN	ANTIBODY BINDING				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
015879	NDDF
1599788	RXNORM
232493	MMSL
30871	MMSL
4034154	VUID
4034154	VANDF
708822004	SNOMEDCT_US
714689007	SNOMEDCT_US
8078	IUPHAR_LIGAND_ID
9182	INN_ID

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
COSENTYX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0639	INJECTION	150 mg	SUBCUTANEOUS	BLA	32 sections
COSENTYX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0639	INJECTION	150 mg	SUBCUTANEOUS	BLA	32 sections
COSENTYX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0639	INJECTION	150 mg	SUBCUTANEOUS	BLA	32 sections
COSENTYX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1056	INJECTION	75 mg	SUBCUTANEOUS	BLA	32 sections
COSENTYX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1056	INJECTION	75 mg	SUBCUTANEOUS	BLA	32 sections
COSENTYX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1056	INJECTION	75 mg	SUBCUTANEOUS	BLA	32 sections
COSENTYX	HUMAN PRESCRIPTION DRUG LABEL	1	0078-1070	INJECTION	300 mg	SUBCUTANEOUS	BLA	32 sections

Showing 1 to 7 of 7 entries

Previous1Next